Simões Susana M N, Figueiras Ana R, Veiga Francisco, Concheiro Angel, Alvarez-Lorenzo Carmen
University of Coimbra, Faculty of Pharmacy , Coimbra , Portugal +351 239 855099 ;
Expert Opin Drug Deliv. 2015 Feb;12(2):297-318. doi: 10.1517/17425247.2015.960841. Epub 2014 Sep 17.
Amphiphilic block copolymers are recognized components of parenteral drug nanocarriers. However, their performance in oral administration has barely been evaluated to any great extent.
This review provides an overview of the methods used to prepare drug-loaded polymeric micelles and to evaluate their stability in gastrointestinal (GI) fluids, and then analyzes in detail recent in vitro and in vivo results about their performance in oral drug delivery. Oral administration of polymeric micelles has been tested for a variety of therapeutic purposes, namely, to increase apparent drug solubility in the GI fluids and facilitate absorption, to penetrate in pathological regions of the GI tract for locoregional treatment, to carry the drug directly toward the blood stream minimizing presystemic loses, and to target the drug after oral absorption to specific tissue or cells in the body.
Each therapeutic purpose demands micelles with different performance regarding stability in the GI tract, ability to overcome physiological barriers and drug release patterns. Depending on the block copolymer composition and structure, a wealth of self-assembled micelles with different morphologies and stability can be prepared. Moreover, copolymer unimers can play a role in improving drug absorption through the GI mucosa, either by increasing membrane permeability to the drug and/or the carrier or by inhibiting drug efflux transporters or first-pass metabolism. Therefore, polymeric micelles can be pointed out as versatile vehicles to increase oral bioavailability of drugs that exhibit poor solubility or permeability and may even be an alternative to parenteral carriers when targeting is pursued.
两亲性嵌段共聚物是肠外给药纳米载体的公认组成部分。然而,它们在口服给药方面的性能几乎尚未得到充分评估。
本综述概述了用于制备载药聚合物胶束及其在胃肠道(GI)液中稳定性评估的方法,然后详细分析了其在口服药物递送方面近期的体外和体内研究结果。聚合物胶束的口服给药已针对多种治疗目的进行了测试,即提高药物在胃肠道液中的表观溶解度并促进吸收、渗透到胃肠道的病理区域进行局部治疗、将药物直接输送到血流中以尽量减少首过损失,以及在口服吸收后将药物靶向体内特定组织或细胞。
每种治疗目的都需要胶束在胃肠道稳定性、克服生理屏障的能力和药物释放模式方面具有不同的性能。根据嵌段共聚物的组成和结构,可以制备出大量具有不同形态和稳定性的自组装胶束。此外,共聚物单体会通过增加药物和/或载体的膜通透性、抑制药物外排转运蛋白或首过代谢,在改善药物通过胃肠道黏膜的吸收方面发挥作用。因此,聚合物胶束可被视为提高难溶性或低渗透性药物口服生物利用度的通用载体,在追求靶向性时甚至可能成为肠外载体的替代品。